CD26 a cancer stem cell marker and therapeutic target - 08/05/15
![](/templates/common/images/mail.png)
pages | 4 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Cancer stem cells (CSCs) comprise a tumor subpopulation responsible for tumor maintenance, resistance to chemotherapy, recurrence and metastasis. The identification of this cell group is very important, but there is still no consensus on its characterization. Several CSC markers have been described, like CD133, CD24, CD44 and ALDH1, but more research to identify new markers to facilitate the identification of CSC in a heterogeneous tumoral mass is required. Thus, this article describes the CD26 expression as a CSC marker and the role that it plays in different types of cancer. CD26 expression correlates with some characteristics of CSCs, like the formation of spheres in vitro, formation of new tumors, and resistance to chemotherapy. CD26 is therefore suggested as an auxiliary marker for CSC in different types of cancer, and as a potential therapeutic target.
Le texte complet de cet article est disponible en PDF.Keywords : Cancer stem cells, CD26, CSC marker, Indifferentiation marker, Therapeutic target
Abbreviations : CSC, AML, SP, ALDH1, ADA, MM, GBM, LSC, CML, ER
Plan
Vol 71
P. 135-138 - avril 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?